Product Data Sheet

Protriptyline hydrochloride

Cat. No.: HY-B0949


CAS No.: 1225-55-4

Molecular Formula: $C_{19}H_{22}ClN$ Molecular Weight: 299.84

Target: Cholinesterase (ChE)
Pathway: Neuronal Signaling

Storage: 4°C, sealed storage, away from moisture

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (333.51 mM; Need ultrasonic) $H_2O: 100$ mg/mL (333.51 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.3351 mL	16.6756 mL	33.3511 mL
	5 mM	0.6670 mL	3.3351 mL	6.6702 mL
	10 mM	0.3335 mL	1.6676 mL	3.3351 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS Solubility: 100 mg/mL (333.51 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (6.94 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: \geq 2.08 mg/mL (6.94 mM); Clear solution
- 4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (6.94 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Protriptyline hydrochloride is a tricyclic antidepressant (TCA), specifically a secondary amine, for the treatment of depression and ADHD. Unique among the TCAs, protriptyline tends to be energizing instead of sedating, used for narcolepsy to achieve a wakefulness-promoting effect.
In Vitro	Protriptyline hydrochloride (0-70 μ M; 24 hours; PC3 cells) causes cytotoxicity in PC3 cells ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay ^[2]		
Cell Line:	PC3 cells	
Concentration:	50, 60 and 70 μM	
Incubation Time:	24 hours	
Result:	Decreased cell viability in a concentration-dependent manner.	

In Vivo

Protriptyline hydrochloride (10 mg/kg; i.p.; for 21 days; rat model of AD) improves spatial learning and retention memory in STZ treated rats^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rat model of AD ^[3]	
Dosage:	10 mg/kg	
Administration:	Intraperitoneal injection; for 21 days.	
Result:	Reduced pTau, Aβ42 and BACE-1 levels, neurodegeneration, oxidative stress and glial activation. Improved p-ERK/ERK ratio and enhanced BDNF and CREB levels by reducing κB and GFAP expression.	

CUSTOMER VALIDATION

- Cell Commun Signal. 2023 May 25;21(1):123.
- Biochem Biophys Res Commun. 2022 Dec 31;637:181-188.
- Biochem Biophys Res Commun. 2022.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Bansode SB, et, al. Molecular investigations of protriptyline as a multi-target directed ligand in Alzheimer's disease. PLoS One. 2014 Aug 20;9(8):e105196.
- [2]. Chang HT, et, al. The mechanism of protriptyline-induced Ca2+ movement and non-Ca2+-triggered cell death in PC3 human prostate cancer cells. J Recept Signal Transduct Res. 2015;35(5):429-34.
- [3]. Tiwari V, et, al. Protriptyline improves spatial memory and reduces oxidative damage by regulating NFkB-BDNF/CREB signaling axis in streptozotocin-induced rat model of Alzheimer's disease. Brain Res. 2021 Mar 1;1754:147261.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com$

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA